Navigation Links
ViaViente Demonstrates Cardiovascular Benefits in New Human Trial
Date:8/8/2008

By Kathleen J. Burkhalter

BOSTON, Aug. 8 /PRNewswire/ -- Francis, 50, never imagined that drinking a high anti-oxidant fruit beverage every day could help protect his health -- in just 1 week. That's what he found out after participating in a clinical trial near his home in Los Angeles, Calif.

A new study conducted by Bell Ventures, shows that after just 7 days, platelet aggregation, a known indicator of cardiovascular disease (CVD), was significantly reduced in many of the participants who took the anti-oxidant product, ViaViente, twice a day.

David Bell, President of Bell Ventures, said, "These results are important because they show how a natural anti-oxidant and anti-inflammatory product like ViaViente can help protect against one of our most serious health concerns."

Health experts recommend a daily intake of anti-oxidants, especially in their natural form. Oxidative stress causes damage to cells and contributes to aging and disease. Anti-oxidants combat effects of oxidative stress such as inflammation.

A recent independent report, A Consumer Conscious Look at Six Premium Anti-Oxidant Products, by Frank Ervolino, ND, shows that ViaViente outperformed other popular products using ORAC -- an industry standard for anti-oxidant testing. This is an important indication of quality and potential benefits.

Clinical research shows the connection between what's in the product and actual outcomes in human health.

The ViaViente study takes direct aim at the benefits to cardiovascular health of consuming a non-drug, natural food product. It correlates the consumption of ViaViente to platelet inhibition -- a marker of CVD.

Why is cardiovascular health so important? The American Heart Association reports that approximately 80 million people in the United States have CVD; nearly 2,400 people die of CVD every day; more people die from CVD than from cancer, auto accidents, and Type 2 diabetes combined; an estimated 1.2 million Americans will have new or recurrent heart attacks in 2008.

Little wonder cardiovascular care is one of our most serious health concerns.

The study uses an established test to measure the reduction of thromboxane in human metabolism. Thromboxane contributes to vasoconstriction, which can increase blood pressure, and platelet stickiness which can lead to clot formation. Both are associated with higher incidence of serious cardiovascular events. Reducing the production of thromboxane can help reduce vasoconstriction and platelet stickiness.

Experts agree that there is a well established relationship between thromboxane and cardiovascular function. In fact, clinical research on it was pioneered by drug companies looking for its relationship to aspirin therapy.

Research indicates that natural anti-oxidants can be effective in reducing thromboxane. The objective of this study was to measure the effectiveness of a proven antioxidant product, ViaViente, at reducing thromboxane in humans, and having a demonstrable benefit to cardiovascular health.

The study investigated the effects of the recommended daily dose of ViaViente for 1 week after a washout period. Sixteen subjects successfully completed the protocol.

Results fell into two categories: significant improvement or no significant change. After just one week, 38% of the subjects showed significant improvement: an average of 16%.

The research team is planning a second phase that will measure results in the same subjects over one month. Bell said that he expects to see an even greater benefit among more participants.

In the mean time, Francis plans to continue taking ViaViente every day.

Kathleen J. Burkhalter is currently in the Masters in Journalism program at Harvard University. She lives in Massachusetts. You can contact the author at kjb@post.harvard.edu.

Contact:

David Bell

dbell@bellventures.com


'/>"/>
SOURCE Bell Ventures LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
Breaking Medicine Technology:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
Breaking Medicine News(10 mins):